000 postmenopausal women in 21 countries in the study.

The women took either anastrozole or tamoxifen as adjuvant therapy after surgery – to help their breast cancer returning. Approximately 32,000 were shown to be very effective in preventing the disease back in this high-risk group of women. But over a period of ten years, the newer drug – anastrozole – proved to be effective, with approximately 80 % of patients are still free of cancer ten years later, compared with 76 % of those given tamoxifen. Professor Cuzick said: ‘Tamoxifen has been in use for at least 25 years and remains one of the most effective breast cancer treatments ever developed , but these results further support for the use of anastrozole as first-line treatment for postmenopausal women with ,, such as.

Is the final event in the 2009-10 Indiana Life Sciences Collaboration Conference Series, the question, Personalized Medicine – Are We There Yet, the subject. It takes place in Fairbanks Hall participate in the IU / Clarian Education and Resource Center, 10th St. , Indianapolis, 00 to 15 on Friday.. Speakers, Dr.llpoint Top Execs To 14th In Conference on personalized medicine at May Participateto a doctor to a doctor knows, the process of providing a medical history. But until recently it was difficult for the doctors to each other their personal observations and intuitions, the other to be able to offer the same individual attention stocks.At the above development, Related BGN Electronics – of the University of technology transfer company and which ATI Cleantech Group a new business a new company, ROTEC to commercialize the technology. Israeli National Water Company, Mekorot chosen ROTEC as a a promising of a handful of enterprises invests at R & D funding to support new technologies for water treatment world and of Israel.

Is researchers at Ben – Gurion University of the Negev rescale developing technology, a new method to achieve very high yields in the desalination by reverse osmosis into can be used one Jordanian desalinization plant.